Business & Finance
Virus-based therapy company announces progress in research program, corporate developments
Published in Medical Letter on the CDC and FDA, October 30th, 2005
In the past year, Neotropix has experienced a number of significant events including:
- Completing research and development necessary to file an investigational new drug application for Neotropix's cancer drug candidate with the FDA, setting the company on course for phase I clinical trial early in 2006.
- Securing a second tranche of funding of $3.8 million from VIMAC Milestone Medica Fund, Quaker BioVentures, The Aurora Funds, and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania.
- Significantly increasing personnel in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Botulinum Toxin
Adverse events from botulinum toxin type A injections reported - Diagnostics
Nonradioactive method to measure activated K-ras protein optimized - Geriatrics
Uninsured adults aged 65 years and older have high health risks - Hepatitis A Virus
Outbreak of hepatitis A associated with green onions - Monkeypox Outbreak
Acute-phase humoral immunity to monkeypox characterized - Adverse Drug Reaction
Enrollment discontinued in Avastin platinum-refractory ovarian cancer study - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
